• The nucleus incertus (NI) is a brainstem nucleus projecting widely across the brain.
Introduction
The nucleus incertus (NI) is a highly conserved brainstem structure present in invertebrates, rodents, non-human primates and humans. It is located at the base of the fourth ventricle and consists of long GABAergic projection neurons with widespread connections throughout the rat brain [21, 45] . Strong inputs from the prefrontal cortex, motor cortex, lateral habenula, oculomotor control regions and medial septum to the NI indicate a role in integrating information to modulate behavioural activity possibly exerted through its major efferent connections to the median raphe, interpeduncular nucleus, and hippocampal system [21, 52] . The NI is the main neuronal source of the neuropeptide relaxin-3 that is known to be involved in various behaviours associated with anxiety, fear, arousal, stress response, reward, addiction, cognition, memory and feeding (for review see: [52, 55, 59] ). For a small group of neurons, the NI expresses a variety of receptors: CRF 1 receptors at high density, GABA receptors, 5-HT receptors, cholinergic receptors and orexin receptors [4, 22, 29, 40, 48, 61] . However, dopamine receptors have not previously been discovered in the NI. D 2 receptors bind to Gα i/o and inhibit adenylyl cyclase, in turn reducing cAMP levels [2] . Alternative splicing of a 29 amino acid region Physiology & Behavior 151 (2015) [525] [526] [527] [528] [529] [530] [531] [532] [533] [534] from the 3rd intracellular loop results in two isoforms of the D 2 receptor, long (D 2L ) and short (D 2S ) [10, 20, 26, 27, 41] . This region has been found to be important in G-protein coupling thus resulting in distinct functional roles of the two isoforms ( [17] ; for review see: [11] ). D 2 receptors are highly expressed in the striatum, nucleus accumbens and olfactory tubule; and moderately expressed in the substantia nigra, ventral tegmental area, prefrontal cortex, amygdala, hippocampus and hypothalamus of rodents [11, 64] . In the brainstem, certain nuclei strongly express D 2 receptors, including the locus coeruleus, trigeminal nucleus and the nucleus of the solitary tract [64] .
Our previously published work showed that both typical and atypical antipsychotics induced significant c-Fos expression in the NI [50] . Since the main underlying mechanism of action of antipsychotics is D 2 receptor antagonism-mediated, these findings prompted us to investigate the presence of D 2 receptors in the NI. In the present manuscript, reverse transcription polymerase chain reaction (RT-PCR), western blotting and immunofluorescence labelling techniques have been employed to show the expression of D 2 receptors in the NI. Concurrent immunofluorescent labelling of NeuN, CRF 1 and relaxin-3 was carried out to validate the location of the NI and study receptor co-expression patterns. To further confirm the presence of D 2 receptors, quinpirole (a D 2 /D 3 agonist) was microinfused into the NI and the rats were exposed to the Laboratory Animal Behaviour Observation Registration and Analysis System (LABORAS) home cage monitoring system and a novel environment-induced suppression of feeding paradigm.
Materials and methods

Animals
Forty-six male Sprague-Dawley rats (280-350 g), obtained from the Laboratory Animals Centre, National University of Singapore, were utilised in this investigation. The procedures conducted were in compliance with the guidelines of the National Institutes of Health Guide for Care and Use of Animals, and with approval from the Institutional Animal Care and Use Committee (IACUC) of the National University of Singapore. Rats were housed in pairs in individually ventilated cages that were maintained in a temperature controlled room (22°C-24°C) with a 12 hour light-dark cycle. The animals were given ad libitum access to food and water and were acclimatised to the housing conditions for at least 5 days.
Drugs
Quinpirole hydrochloride (Tocris, UK), ketamine (Parnell Manufacturing Pty Ltd.; Alexandria, NSW, Australia), xylazine (Ilium Xylazil, Troy Laboratories Pty Ltd.; Glendenning, NSW, Australia), enrofloxacin (Baytril 5%, Bayer Health Care; Seoul, Korea) and carprofen (Carprieve, Norbrook Laboratories (GB), Ltd.; Carlisle, UK) were freshly prepared in sterile isotonic saline (B. Braun, Germany) before use. Pentobarbital (Valabarb) was purchased from Jurox Pty Ltd., Australia.
Fresh tissue harvest
Rats were anaesthetised with a pentobarbital overdose and decapitated. The brains were removed immediately and 500 μm sections were collected with a rat brain matrix (Roboz Surgical, USA). The position of the NI (Fig. 1A) was verified by light microscopy and punched out using a micropunch (0.75 mm, Sigma-Aldrich, USA) as described previously [30] . NI tissue punches and microdissected regions of the caudate putamen were homogenised for RT-PCR amplification and western blot analysis.
RNA extraction and reverse transcription PCR (RT-PCR)
Total RNA was extracted from the rats' NI or striatum and purified with the Purelink Mini Total RNA Purification kit (Invitrogen, USA) according to the manufacturer's guidelines. The amount of RNA was quantified and approximately 1 μg of RNA was reverse transcribed with oligo (dT) primers using ImProm-II™ Reverse Transcription system. The PCR reaction for the dopamine receptor subtypes [63] and β-actin was carried out with the following sets of primers: D 2 forward primer 5′-GCA GTC GAG CTT TCA GAG CCA ACC TG-3′, reverse primer 5′-AGA ACT TGG CAA TCC TGG GAT TGA C-3′ (255 bp expected band size for short isoform and 342 bp expected band size for long isoform); D 3 forward primer 5′-GTG ACT GTC CTG GTC TAT GCC AG-3′, reverse primer 5′-GCA GAT GCT GTA GTA GCG CTT CAG-3′ (312 bp expected band size) and β-actin forward primer 5′-ATC CTG AAA GAC CTC TAT GC-3′, reverse primer 5′-AAC GCA GCT CAG TAA CAG TC-3′ (287 bp expected band size). The PCR cycling reactions were carried out at 94°C for 5 min, 30 cycles of 94°C for 30 s, 58°C-65°C for 1 min, 72°C for 1 min followed by 10 min at 72°C. The amplified products were separated in 1.5% agarose gel, and then visualized under UV irradiation.
Western blotting
Fresh NI tissue was dissected and lysed with radioimmunoprecipitation assay (RIPA) buffer (150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 50 mM Tris, pH 8.0). The total protein concentration was determined using a Pierce bicinchoninic acid assay (BCA) kit (Pierce Biotechnology, USA). 50 μg of protein was separated by 10% or 12% sodium dodecyl sulphate SDS-PAGE for about 1.5 h and then electroblotted onto a low immunofluorescence PVDF membrane (Biorad, USA) at 100 mA for 2 h. The membranes were subsequently blocked with 5% skim milk, 5% bovine serum albumin (BSA) or 2% normal goat serum (NGS) in Tris-buffered saline/Tween 20 (TBST) for an hour in room temperature followed by incubation with primary antibodies: anti-D 2 (1:1000, Ab32349, Abcam, Hong Kong); anti-D 2S (1:1000; 324,396, Merck Millipore, USA); anti-CRF RI/II (1:1000, Santa Cruz, USA), anti-relaxin-3 (1:1000); or anti-β-actin (1:10,000, A-5441, Sigma-Aldrich, USA) overnight at 4°C. The mouse monoclonal antirelaxin-3 antibody was produced from hybridoma cells as previously described [30] . Following primary antibody incubation, the blot was then washed and incubated with a peroxidase-conjugated anti-goat (1:5000; Pierce Biotechnology, USA), anti-mouse (1:5000; ThermoScientific, USA) or anti-rabbit IgG (1:5000; Pierce Biotechnology, USA) for an hour at room temperature with agitation. Protein bands were detected by incubating the membranes with peroxidase substrate Luminata Forte (Merck Millipore, USA) and imaging was conducted with a luminescent image analyzer (Image Quant LAS 4000, GE Healthcare, UK). The relaxin-3 blot was incubated with goat anti-mouse AlexaFluor488 (1:5000) for an hour at room temperature with agitation and the fluorescence signal was detected with the Image Quant LAS 4000.
Immunofluorescence
Rats were anaesthetized with a pentobarbital overdose. Transcardial perfusion was carried out with isotonic saline followed by 2% paraformaldehyde in phosphate buffer (0.1 M). The brains were subsequently post-fixed in 2% paraformaldehyde at 4°C for 2 h and soaked in 15% sucrose followed by 30% sucrose at 4°C for 2 days each. Sections (30 μm) were collected serially in sterile PBS in a cryostat (CM 3050, Leica Biosystems, Germany). The ventral half of the brain sections containing the NI was stored in cryoprotectant solution (1% PVP-10, 30% ethylene glycol, 30% sucrose, 50% 0.1 M phosphate buffer, pH 7.4) at -20°C until immunofluorescence labelling was conducted [24] . Sections were hydrated by washing in phosphate buffered saline (PBS) and permeabilized by incubation in 0.3% Triton-X 100 in PBS (PBST) for 10 to 30 min. The sections were then incubated in 5% fetal bovine, goat or donkey serum for 1 h at room temperature followed by incubation in the following primary antibody solutions for 24-72 h at 4°C: anti-D 2 (1:100, Ab32349, Abcam, Hong Kong); anti-D 2S (1: 150; 324,396, Merck Millipore, USA); anti-CRF RI/II(1:600, Santa Cruz, USA); anti-relaxin-3 (1:100); and anti-NeuN (1:200, MAB 377, Merck Millipore, USA). The mouse monoclonal anti-relaxin-3 antibody was produced from hybridoma cells as previously described [30] . For the co-staining with anti-relaxin-3 (raised in mouse) and anti-CRF RI/II (raised in goat), anti-D 2S (raised in rabbit) was used instead of anti-D 2 (raised in goat) due to compatibility of the antibody source. All sections were rinsed in PBS prior to incubation in solutions containing appropriate Alexa Fluor secondary antibodies (Invitrogen, Life Technologies, CA, USA) for an hour at room temperature in the dark. All sections were rinsed 4 × 5 min each in PBS and mounted on glass slides. The sections were gently shaken during all incubation periods including the rinses. The sections were dried, covered with Prolong Antifade Gold reagent with DAPI (Invitrogen, Life Technologies, CA, USA) and coverslipped. The sections were viewed and photographed with a confocal Microscope (Zeiss LSM 510 Meta, Zeiss, Germany) or a fluorescence microscope (BX-51, Olympus, Japan).
Intra-NI administration of quinpirole and behaviour
Surgery
Rats were anaesthetised with a cocktail of ketamine (75 mg/kg) and xylazine (10 mg/kg) injected intraperitoneally and mounted on to a stereotaxic frame. The scalp was shaved and a midline sagittal incision exposed the bare skull. A burr hole was drilled at AP: − 9.7 mm, ML: − 0.1 mm from the bregma to target the nucleus incertus [46] . A guide cannula (Plastics One, USA) 8 mm in length was carefully inserted to a depth of 7.4 mm from the skull surface and was held in place with dental cement and anchoring screws fitted to the skull. The guide cannula was closed using a cap with a stylette. The rats were then allowed a rehabilitation period of 1 week, with analgesic (carprofen) and antibiotic (enrofloxacin) treatments injected subcutaneously for the first 5 days.
General considerations for behavioural assessments
All behavioural assessments were conducted during the light phase of the 12 h light-dark cycle. The NI cannula-implanted rats had free access to water but food was restricted for 18 h prior to some of the experiments as specified below. They were brought to the experimental room at least 1 h before the commencement of behavioural assessments. They were gently handled and quinpirole (6 μg/0.1 μl) or vehicle (equivalent volume of sterile isotonic saline) was infused into the NI over a period of 30 s into the brain. The administration was done using an infusion cannula that had a 1 mm projection beyond the guide cannula. The infusion cannula was left in place for 1 min before re-capping and placing the rat in the exploration arenas. Behavioural assessment began immediately. Behavioural apparatus was cleaned with 70% ethanol between the trials. All the behavioural observations were video recorded and analysed using a video tracking system (Ethovision, version 8.2, Noldus, Netherlands). 
Home cage monitoring
Cannula-implanted rats were fasted for 18 h and then acclimatised to the experimental room for 1 h. Following intra-NI infusion of saline or quinpirole (6 μg/0.1 μl), the rats were individually placed in the Laboratory Animal Behaviour Observation Registration and Analysis System (LABORAS, Metris, Netherlands) home cages, which were similar to the regular home cages in which they were housed. Behavioural parameters such as locomotion, velocity, distance travelled, feeding, drinking, rearing and grooming were then continuously assessed for 2 h by the LABORAS software.
Novel environment-induced suppression of feeding
The behavioural assessment was carried out as per previously published reports [7] with certain modifications as mentioned. Cannula-implanted rats, fasted for 18 h, were acclimatised for 1 h in a dimly lit experimental room. Feed pellets were placed in the centre of the circular arena (diameter: 120 cm and height 50 cm, Fig. 1B ) with a dark floor and white coloured walls. The observation area was virtually divided into zones, namely feed area, middle area and periphery in the acquisition software (Ethovision Version 8). Rats were individually infused with saline or quinpirole (6 μg/0.1 μl), placed in the periphery of the arena and behaviour was monitored for 10 min. The latency to enter the feed area and the durations of time spent in the feed area and periphery were measured with the Ethovision behavioural tracking and analysis software. The latency to feed was observed manually from the video file by an experimenter blind to the treatment. The quantity of food consumed and the number of faecal pellets left after each trial were also recorded.
Post-mortem analysis
The rats were anaesthetized with an overdose of pentobarbital and 0.1 μl of pontamine sky blue dye was infused into the NI via the guide cannula in the same manner as the drug infusion described above. Subsequently, transcardial perfusion was carried out with isotonic saline followed by 4% paraformaldehyde in phosphate buffer (0.1 M). The brains were subsequently post-fixed in 4% paraformaldehyde at 4°C overnight and soaked in 30% sucrose at 4°C for 2 days. Sections (30 μm) were collected serially in PBS with a cryostat (CM 3050, Leica Biosystems, Germany). The sections were then Nissl stained to identify the track of the implanted cannula (Fig. 1C) . Rats with incorrect cannula positions were excluded from analysis.
Statistical analysis
All statistical analyses conducted were between-subjects. The behavioural data from home cage monitoring (LABORAS) at various time points was subjected to repeated measures ANOVA across time followed by multivariate analysis to identify the differences at specific time points. The data from other behavioural studies were subjected to unpaired two-tailed Student's t-test. IBM SPSS version 20.0 software package was used for the statistical analysis and the level of statistical significance was set at P b 0.05. The data are expressed as mean ± SEM.
Results
Molecular biology
RT-PCR
The expression of D 2 (long and short forms), but not D 3 receptor mRNA was evident in the triplicate NI samples (Fig. 2A) .
Western blotting
The nonselective D 2 receptor antibody recognizing the 1-100 amino acids of the human D 2 receptor, produced a band at~105 kDa present in both the NI sample and the caudate putamen (Fig. 2B) . This band is likely to be the D 2 receptor dimer [31] . Using an antibody selective for the short isoform of the D 2 receptor, the strongest band was~41 kDa, which is the expected weight for the glycosylated D 2S receptor. This band is strongly expressed in the NI and caudate putamen (Fig. 2C) . The strong relaxin-3 bands (Fig. 2B and C ) present in the NI samples validated the position of the NI microdissection.
Immunofluorescence
Immunofluorescence with the non-selective D 2 receptor antibody showed D 2 receptor-like immunoreactivity in the NI (Fig. 2D ) and in the caudate putamen region, which was used as the positive control (Fig. 2E) . As mentioned earlier, the co-expression studies were conducted with D 2S due to the compatibility of the antibodies. Robust D 2S receptor-like immunoreactivity was found in the NI. D 2S positive neurons of the NI co-expressed CRF 1/2 receptors (Fig. 3 ) and relaxin-3 (Fig. 4) . Triple immunofluorescence labelling showed the co-expression of D 2S , CRF 1/2 and relaxin-3 in several NI neurons (Fig. 5A-D) . The D 2S positive cells also co-labelled for NeuN (Fig. 5E-G) confirming the expression of D 2S receptor-like immunoreactivity in neurons.
Behaviour
Home cage exploration
Heat maps of space utilisation within the home cage showed hypolocomotion after intra-NI quinpirole treatment (Fig. 6A,B) . (Fig. 6C-F) . Other parameters, grooming (F 1,14 = 2.304, P = 0.151, NS), feeding duration (F 1,14 = 1.823, P = 0.198, NS), and feeding frequency (F 1,14 = 1.829, P = 0.198, NS), were not significantly affected by intra-NI quinpirole administration (Fig. 6C-H ).
Novel environment-induced suppression of feeding
Two-tailed unpaired t-test on the data revealed that infusion of quinpirole (6 μg/0.1 μl) into the NI suppressed the distance travelled (P = 0.001), velocity of the rat movement (P = 0.001), frequency of visits to the central feed area (P = 0.004), duration of time spent in the feed area (P = 0.007), quantity of feed consumed (P = 0.022), increased latency to visit feed area (P = 0.021), and latency to feed (P = 0.002) compared to the saline infusion (Fig. 7A-G) . Thigmotaxis (measured by the duration of time spent close to the wall) and defecation were significantly greater in the quinpirole infused rats (P = 0.0002 and P = 0.026, respectively) than saline infused rats ( Fig. 7H and I ).
Discussion
The presence of D 2 receptors in the NI is demonstrated through RT-PCR, western blotting and immunofluorescence labelling techniques and further confirmed by studying the effect of quinpirole, microinfused into the NI, on behavioural paradigms.
The RT-PCR shows that while the D 2 receptor gene is transcribed into mRNA in the NI, the D 3 receptor gene is not. The D 2 (L + S) receptor antibody produced an~100 kDa band corresponding to the dimeric form of D 2 receptors [31] . These dimers are unaffected by the reducing and denaturing conditions of the western blot [9] . Notably, similar bands were observed in the caudate putamen, a region highly innervated by dopaminergic projections from the substantia nigra and known to have rich D 2 receptor expression [62, 64] . Immunostaining conducted with the same D 2 antibody provides further evidence that D 2 receptor-like immunoreactivity is found specifically at the base of the 4th ventricle corresponding to the NI region. The D 2S antibody produced a strong~41 kDa band in the NI and striatum indicating the presence of the D 2S isoform in both of these regions. However, due to the lack of a specific D 2L receptor antibody appropriate for immunostaining/western blotting, the expression of D 2L receptors in the NI could not be investigated in the present study.
The immunofluorescence co-expression experiments were carried out with the D 2S antibody due to the robust staining quality and compatibility with the CRF 1/2 and relaxin-3 antibodies. Strong D 2S receptor-like immunoreactivity was detected in the cell bodies of the NI neurons comparable to previously reported labelling in other brain regions [32, 47] . The co-localisation of the D 2S receptors with NeuN validates the expression of these receptors in neuronal cells. CRF 1 receptors are densely expressed in the NI and considered a marker to delineate its cytoarchitecture [16, 38, 51, 56] while relaxin-3 expression is a feature relatively unique to NI neurons [6, 39] . The strong co-localisation of D 2S receptor-like immunoreactivity with CRF 1 and relaxin-3 confirms its position in the NI. A limitation of the current study is that the precise localisation of D 2 receptors in the NI was only demonstrated by immunostaining. This should be confirmed by in situ with which isoform-specific D 2 receptor mRNA could be precisely localised in the NI. While, the present study investigates the D 2 and D 3 receptors, motivated by the c-fos inducing effects of antipsychotics in the NI [50] , additional studies aimed at other dopamine receptor subtypes will be of interest.
The source of dopaminergic innervation to the NI is unlikely to be from the midbrain dopaminergic structures, namely the ventral tegmental area and substantia nigra, as they do not significantly project to the NI [21] . Despite poor afferents from the VTA, the NI projects strongly to the VTA providing a possible route for dopaminergic feedback regulation [21] . Alternatively, dopamine input to the NI could arise from the raphe nuclei which possess significant numbers of dopaminergic cells, specifically the median raphe which projects robustly to the NI [21, 44, 58] . Similarly, the ventral periaqueductal grey, which sends strong inputs to the NI, contains groups of dopaminergic cells [21, 25, 37] . To ascertain the source of dopamine innervation to the NI, retrograde tracing combined with immunolabelling of the dopamine transporter, tyrosine hydroxylase and dopamine beta-hydoxylase should be conducted.
Based on previous literature, direct administration of ligands into the NI is an apt method to study the functional properties of the nucleus. Inactivation of the NI by direct lidocaine infusion during the Morris water maze task indicated the structure's involvement in spatial and working memory [42] . Similarly, a study conducted in our lab showed that CRF infusion into the NI suppressed long-term potentiation, reflecting the role of the NI in the stress-driven modulation of working memory [16] . To study the functional relevance of the D 2 receptors in the NI, quinpirole was micro-infused into the NI and the behavioural effects were studied. Among the available D 2 receptor agonists, quinpirole (previously reported as LY 171555) has been relatively well investigated in molecular, autoradiography, electrophysiological and preclinical behavioural studies. It is a full agonist at the D 2 receptor and has been used to study effects of D 2 receptor stimulation in vivo in both rodents and primates by many investigators [1, 12, 14, 18, 23, 28, [33] [34] [35] [36] 53] . Though quinpirole has five-fold stronger affinity to D 2 receptors than D 3 receptors [19, 54] , we have made an effort to rule out the D 3 effects by using a dose (6 μg) that was recently reported to be reasonably selective for D 2 receptors over D 3 [5] . Furthermore, the RT-PCR conducted shows negligible expression of the D 3 receptor In the present study, intra-NI quinpirole infusion significantly suppressed locomotion-related parameters in the behavioural tests conducted (home-cage monitoring and novel environment-induced suppression of feeding). The home cage monitoring was carried out using LABORAS, which is a sensitive behaviour data acquisition system that utilizes a vibration sensitive platform to record and classify the different kinds of movements exhibited by the rat [49] . Intra-NI infusion of quinpirole significantly suppressed distance travelled, duration of time spent in locomotion and rearing duration, measured during the first 5 min and entire 2 h observation period. During the first 5 min, the behavioural effects observed are likely to be primarily due to the effect of quinpirole on the NI D 2 receptors. Therefore we focused on the immediate locomotion and rearing suppression. Rearing is frequently used to reflect both exploration and emotionality [57] . Based on the reduction in rearing behaviour, it is possible that NI D 2 receptors could play a role in behavioural suppression.
Similar to the homecage monitoring, intra-NI quinpirole at the tested dose suppressed locomotion in the novel environment-induced suppression of feeding paradigm. In this paradigm, quinpirole altered thigmotaxis, latency to reach the feed area, frequency of visits to feed area, duration of time spent in feeding, latency to feed, quantity of feed consumed and defecation. Although these results appear to indicate an anxiogenic effect, the locomotor suppression effect of quinpirole might have increased the latency to reach the feeding area and reduced time spent in the feeding area, confounding the hypophagic effects observed in this study. It is interesting to note that feeding was not affected in the low stress home cage environment despite suppression of locomotion. In fact, quinpirole infusion tended to increase feeding duration (P = 0.0678) and frequency (P = 0.0618) during the first 5 min. However, in the presumably high stress novel environment, intra-NI quinpirole infusion reduced feeding significantly. It is tempting to speculate that the D 2 receptors in the NI modulate feeding differentially in high and low stress environments, particularly since there is high co-expression of CRF 1 and D 2S receptor-like immunoreactivity in the NI.
Previous investigations have shown that administration of quinpirole into various structures in dopaminergic circuitry affected locomotion and rearing [3, 8, 13, 15, 60] . Similarly, the results of the present study support the idea of D 2 receptors in the NI being involved in locomotion. The behavioural tests in this investigation were conducted immediately after infusion of a small volume (0.1 μl) to limit diffusion to other areas. Although the possibility of the drug diffusing to neighbouring structures cannot be completely ruled out, the usage of a small volume of a specific agonist (quinpirole) at a concentration previously proven to be effective at D 2 receptors suggests that the hypolocomotor effects observed are very likely to be due to action in the NI. The consistent hypolocomotion effect induced by quinpirole infusion to the NI regardless of the paradigm points to a functional role of these receptors in locomotion. Based on its strong bidirectional connections to the median raphe and interpeduncular nuclei, the NI was predicted to play a role in modulating behavioural activity [21] and the present results lend support to this hypothesis. The theta-modulating effects of the NI [43] could be a possible mechanism through which the behavioural activity levels are altered.
Conclusion
The current study reports RT-PCR and western blot evidence for the expression of D 2 receptor mRNA and protein, respectively, in micro-punched tissue from the position of the NI. Additionally, D 2 receptor-like immunoreactivity co-expresses with relaxin-3, CRF 1 and NeuN in the NI. Activation of these D 2 receptors by microinfusion of quinpirole into the NI caused hypolocomotion in the behavioural paradigms tested. To the best of our knowledge, this is the first evidence for the expression of a catecholamine receptor, the D 2 receptor, in the NI.
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